Incyte (INCY) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vaxcyte (PCVX) has outperformed Incyte (INCY) over the past year, gaining 59.6% versus a gain of 32.1%. Over five years, PCVX leads with a +166.3% price change compared with +72.0% for INCY. Incyte is the larger company by market cap ($22.85 billion vs $9.67 billion), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCY | PCVX |
|---|---|---|
| Share price | $112.75 | $65.02 |
| Market cap | $22.85B | $9.67B |
| 1-day change | -0.61% | -2.90% |
| YTD return | +14.15% | +40.91% |
| 1-year return | +32.06% | +59.59% |
| 5-year return | +71.98% | +166.35% |
| P/E ratio (TTM) | 14.36 | — |
| Forward P/E | 12.89 | — |
| EPS (TTM) | $7.85 | $-7.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.14B | — |
| Revenue growth (YoY) | +21.22% | — |
| Net income (latest FY) | $1.29B | $-766.63M |
| Gross margin | 92.76% | — |
| Operating margin | 29.46% | — |
| Net margin | 25.03% | — |
| 52-week high | $132.60 | $90.75 |
| 52-week low | $82.82 | $39.87 |
| Distance from 52-week high | -14.97% | -28.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +14.53% | +79.96% |
| Average volume | 1.63M | 1.66M |
| Shares outstanding | 202.70M | 148.81M |
| Employees | 2,844 | 507 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 2.4 times larger than Vaxcyte by market value ($22.85B vs $9.67B).
- PCVX has outperformed INCY by 27.5 percentage points over the past year.
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Healthcare · Biotechnology · 2,844 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Healthcare · Biotechnology · 507 employees
INCY vs PCVX FAQ
Which is bigger, Incyte or Vaxcyte?
Incyte (INCY) is larger, with a market capitalization of $22.85B compared with $9.67B for Vaxcyte (PCVX).
Which stock has performed better over the past year, INCY or PCVX?
PCVX returned +59.59% over the past 12 months, compared with +32.06% for INCY (price return, excluding dividends). Past performance does not predict future results.
Are Incyte and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.